Franklin A. Neva followed by service with the US Navy at Naval Medical Research Unit-3 in Cairo, Egypt. He spent several years at Harvard University as a researcher. He became a professor at University of Pittsburgh, where he worked with Jonas Salk on a vaccine for polio. While at Pittsburgh, he also isolated ECHO 16, the virus responsible for Boston exanthem disease. This was the first description of that disease. Together with Thomas Weller, he isolated the Rubella virus in 1962. In 1964 he moved back to Harvard to head the Department of Tropical Public Health. In 1969 he joined the National Institutes
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood